A Review of Novel Drug Delivery Controlled Porosity Osmotic Pump Tablets Therapeutic Approach and Future Trend
The review work is comprised the enhancement of bioavailability and increase therapeutic efficacy. The porous osmotic pump tablets were designed using D‐Optimal design and numerical optimization technique was applied to find out the best formulation. Another hand an osmotic pump (OP) were designed and evaluated with the aim to deliver drug in a controlled manner. Osmotic agent and pore former was considered as independent variables. Drug release rate at 2 h, 4 h, 8 h, 12 h, T50% and release exponent (n) were taken as responses. The increase in concentration of pore former and osmotic agent after a limit, changes the release was measured. The optimized formulation follows mechanism measured. The FT‐IR and DSC studies revealed that no physicochemical interaction between excipients and drug. The influence of pH and agitation intensity on the release of drug was studied and the release mechanism was through osmosis. Stability studies revealed that optimized formulation was stable. The result of D‐ Optimal design and ANOVA studies reveals that osmotic agent and pore former have significant effect on the drug release up to 12 h. The observed independent variables were found to be very close to predicted values of most satisfactory formulation which demonstrates the feasibility.
Keywords: osmotic pump, pore former, bioavailability
2. Mehramizi A, Asgari ME, Pourfarzib M, Bayati KH, Dorkoosh FA, Rafiee T M. Influence of β‐cyclodextrin complexation on lovastatin release from osmotic pump tablets (OPT). DARU 2007; 15(2):71‐8.
3. Salsa T, Veiga F, Pina ME, Oral controlled release dosage forms I. Cellulose ether polymer in hydrophilic matrices, Drug Dev. Ind. Pharm. 1997; 23:929–938.
4. Sharma S. Osmotic controlled drug delivery system. [Online]. [2008 Oct 20]; . Available from: URL:http://www.pharmainfo.net/reviews/osmotic‐controlleddrug‐delivery‐system.
5. Theeuwes F, Swanson DR, Guittard G, Ayer A, Khanna S, Br. J. Clin. Pharmacol., 1985; 19:69S–76S.
6. Verma RK, Mishra B, Garg S, Osmotically Controlled Oral Drug Delivery Drug Development and Industrial Pharmacy, 2000; 26(7):695–709.
7. Chowdary KPR, Mohapatra P, Krishna MN. Evaluation of olibanum and its resin as rate controlling matrix for controlled release of diclofenac. Indian J Pharm Sci 2006; 68(4):497‐500.
8. McClelland GA, Sutton SC, Engle K, Zentner GM, Pharm. Res., 1991; 8:88–92.
9. Ayer AD, Wong PSL, U.S. Patent 4,755,180 (1988).
10. Zentner GM, McClelland GA, Sutton SC, J. Controlled Release, 1991; 16:237–244.
11. Hamdy A, Ossama Y A, Hesham S. Formulation of controlled release baclofen matrix tablets: Influence of some hydrophilic polymers on the release rate and in vitro evaluation. AAPS Pharm Sci Tech 2007; 8(4):E1‐E11
12. O¨ zdemir N, Sahin J, Int. J. Pharm., 1997; 158:91–97.
13. Theeuwes F, Saunders RJ, Mefford WS, U.S. Patent 4,088,864 (1978).
14. Ayer AD, Balkie HH, U.S. Patent 5,071,607 (1991).
15. Prakash RB, Geetha M, Purushothama N, Utpal S. Optimization and development of swellable controlled porosity osmotic pump tablet for theophylline. Trop J Pharm Research 2009; 8(3):247‐55.
16. Kanagale P, Lohray BB, Misra A, Davadra P, Kini R. Formulation and optimization of porous osmotic pumpbased controlled release system of oxybutynin. AAPS Pharm Sci Tech 2007; 8(3):E1‐E7.
17. Zentner GH, Rork GS, Himmelstein KJ, J. Controlled Release, 1985; 1:269–282.
18. Verma RK, Mishra B, Garg S, Osmotically controlled oral drug delivery, Drug Dev. Ind. Pharm. 2000; 26:695–708.
19. Verma RK, Krishna DM, Garg S, Formulation aspects in the developments of osmotically controlled oral drug delivery system, J. Contr. Rel. 2002; 797–27.
20. Santus G, Baker RW, Osmotic drug delivery; a review of patent literature, J. Contr. Rel. 1995; 35:1–21.
21. Ramakrishna N, Mishra B, Design and evaluation of osmotic pump tablets of naproxen sodium, Pharmazie 2001; 56:958–962.
22. Ozdemir N, Sahin J, Design of a controlled release osmotic pump system of ibuprofen, Int. J. Pharm. 1997; 158:91–97.
23. Ramakrishna N. Mishra B, Plasticizer effect and comparative evaluation of cellulose acetate and ethylcellulose-HPMC combination coatings as semipermeable membranes for oral osmotic pumps of naproxen sodium, Drug Dev. Ind. Pharm. 2002; 28:403–412.
24. United States Pharmacopoeia 24, National Formulary 19 United States Pharmacopoeial Convention,Inc., Rockville 2001, pp. 2051.
25. Ramadan MA, Tawashi R, Effect of hydrodynamic conditions and delivery orifice size on the rate of drug release from elementry osmotic pump system (EOP), Drug Dev. Ind. Pharm. 1987; 13:235–248.
26. Skelly JP, Yamamoto LA, Shah VP, Yau MK Barr WH, Topographical dissolution characterization for controlled release products: new technique, Drug Dev. Ind. Pharm. 1986; 12:1159–1175.
27. Skelly JP, M. K. Yau, J. S. Elkins, L. A. Yamamoto, V. P. Shah and W. H. Barr, In vitro topographical characterization as a predictor of in vivo controlled release quindine gluconate bioavailability, Drug Dev. Ind. Pharm. 1986; 12:1177–1201.
28. C. Sankar, M. Rani, A. K. Srivastava and B. Mishra, Chitosan based pentazocine microspheres for intranasal systemic delivery; development and biopharmaceutical evaluation, Pharmazie 2001; 56:223–226.
29. Reiss W, Sterlin H, P. Degen, J. W. Faigle, A. Faigle, A. Geradin, J. Mopper, A. Sallman, A. Schmin, A. Schweizer, M. Sule, W. Thesbald and J. Wagner, Pharmacokinetics and metabolism of the anti-inflammatory agent voltaren, Scand. J. Rheumatol. 1978; 22:17–29.
30. Levy G, Leonards J, Procknal JA, Development of in vitro tests which correlate quantitatively with dissolution rate limited drug absorption in man, J. Pharm. Sci. 1965; 54:1719–1722.
31. Shah VP, Prasad VK, Alston T, Cabina B, Gural RP, Meyer MC, Phenytoin I: in vitro correlation for 100 mg phenytoin sodium capsules, J. Pharm. Sci. 1983; 72:306–308.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).